Jump to ContentJump to Main Navigation

 

LaboratoriumsMedizin

Editor-in-Chief: Nauck, Matthias

Editorial Board Member: Fraunberger, Peter / Klein, Hanns-Georg / Klouche, Mariam / Kohse, Klaus P. / Luppa, Peter B. / März, Winfried / Nebe, Carl Thomas / Orth, Matthias / Ruf, Andreas / Schuff-Werner, Peter / Steimer, Werner / Stieber, Petra / Wallaschofski, Henri / Weber, Bernard / Wieland, Eberhard / Sack, Ulrich

6 Issues per year

Increased IMPACT FACTOR 2012: 0.189

VolumeIssuePage

Issues

Immunosuppressant drug monitoring – a routine undertaking?1

Christoph Seger1 / Michael Vogeser12

1Institute of Medical and Chemical Laboratory Diagnostics (ZIMCL), University Hospital Innsbruck, Innsbruck, Austria

2Institute of Clinical Chemistry, Hospital of the University of Munich, Munich, Germany

Correspondence: Christoph Seger, PhD, Institute of Medical and Chemical Laboratory Diagnostics (ZIMCL), University Hospital Innsbruck, Innsbruck, Austria Tel.: +43 51250481155 Fax: +43 51250424088

Citation Information: LaboratoriumsMedizin. Volume 34, Issue 3, Pages -–-, ISSN (Online) 1439-0477, ISSN (Print) 0342-3026, DOI: 10.1515/jlm.2010.027et, July 2010

Publication History

Published Online:
2010-07-05

Abstract

The quantitative assessment of immunosuppressant drug levels is still one of the most challenging therapeutic drug monitoring procedures in clinical routine. During the past years, several technical developments matured to usable methods. In addition to immunoassays, liquid chromatography-tandem mass spectrometry has become a key method in immunosuppressant therapeutic drug monitoring. This overview should aid in understanding the advantages and disadvantages of the various assays and methods. UK-NEQAS proficiency testing results are used for an inter-assay comparison approach.

Keywords: immunoassays; immunosuppressant drugs; liquid chromatography-tandem mass spectrometry (LC-MS/MS); proficiency testing; tandem mass spectrometry; therapeutic drug monitoring

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.